Valeria Pensotti

Dr. Valeria Pensotti

Cogentech s.r.l Società Benefit a Socio unico
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cancer Detection Prevention
Verified
Journal Article
Closed access
PDF file
GVGiovanna De Vecchi
Giovanna De Vecchi
PVPaolo Verderio
Paolo Verderio
SPSara Pizzamiglio
Sara Pizzamiglio
SMSiranoush Manoukian
Siranoush Manoukian
LBLoris Bernard
Loris Bernard
PPPaolo Peterlongo
Paolo Peterlongo

1 April 2021 in Digestive and Liver Disease
Verified
Journal Article
Closed access
EUEmanuele Damiano Luca Urso
Emanuele Damiano Luca Urso
MLMaurizio Ponz de Leon
Maurizio Ponz de Leon
MVMarco Vitellaro
Marco Vitellaro
QBQuoc Riccardo Bao
Quoc Riccardo Bao
AMAline Martayan
Aline Martayan
RZRaffaella Alessia Zuppardo
Raffaella Alessia Zuppardo

30 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GFGisella Figlioli
Gisella Figlioli
ANArcangela De Nicolo
Arcangela De Nicolo
ICIrene Catucci
Irene Catucci
SMSiranoush Manoukian
Siranoush Manoukian
BPBernard Peissel
Bernard Peissel
PPPaolo Peterlongo
Paolo Peterlongo
Germline pathogenic variants (PVs) in the BRCA1 or BRCA2 genes cause high breast cancer risk. Recurrent or founder PVs have been described worldwide including some in the Bergamo province in Northern Italy. The aim of this study was to compare the BRCA1/2 PV spectra of the Bergamo and of the general Italian populations. We retrospectively identified at five Italian centers 1019 BRCA1/2 PVs carrier individuals affected with breast cancer and representative of the heterogeneous national population. Each individual was assigned to the Bergamo or non-Bergamo cohort based on self-reported birthplace. Our data indicate that the Bergamo BRCA1/2 PV spectrum shows less heterogeneity with fewer different variants and an average higher frequency compared to that of the rest of Italy. Consistently, four PVs explained about 60% of all carriers. The majority of the Bergamo PVs originated locally with only two PVs clearly imported. The Bergamo BRCA1/2 PV spectrum appears to be private. Hence, the Bergamo population would be ideal to study the disease risk associated with local PVs in breast cancer and other disease-causing genes. Finally, our data suggest that the Bergamo population is a genetic isolate and further analyses are warranted to prove this notion.

11 September 2023 in Tumori Journal
Verified
Journal Article
Open access
CBClorinda Brignola
Clorinda Brignola
SVSara Volorio
Sara Volorio
GVGiovanna De Vecchi
Giovanna De Vecchi
DZDaniela Zaffaroni
Daniela Zaffaroni
VDValentina Dall’oLio
Valentina Dall’oLio
MRMaria Teresa Ricci
Maria Teresa Ricci
Lynch Syndrome is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants or epimutation in one of the DNA mismatch repair genes. De novo pathogenic variants in mismatch repair genes have been described as a rare event in Lynch Syndrome (1-5%), although the prevalence of de novo pathogenic variants in Lynch Syndrome is probably underestimated. The de novo pathogenic variant was identified in a 26-year-old woman diagnosed with an adenocarcinoma of the caecum with mismatch repair protein deficiency at immunohistochemistry and a synchronous neuroendocrine tumor of the appendix with normal expression of mismatch repair proteins. DNA testing revealed deletion of exon 6 of the MLH1 gene. It appeared to be a de novo event, as the deletion was not detected in the patient’s parents. The presence of a mosaicism in the patient was excluded and haplotype analysis demonstrated the paternal origin of the chromosome harboring the deletion. The de novo deletion probably originated either from a very early postzygotic or a single prezygotic mutational event, or from a gonadal mosaicism. In conclusion, the identification of de novo pathogenic variants is crucial to allow proper genetic counseling and appropriate management of the patient’s family.

11 September 2001 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SCS Casadei
S Casadei
LCLaura Cortesi
Laura Cortesi
VPValeria Pensotti
Valeria Pensotti
PRPaolo Radice
Paolo Radice
MPM Pierotti
M Pierotti
DCDaniele Calistri
Daniele Calistri
We describe the Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method set up for a sensitive and preliminary rapid screening of BRCA1 mutations. We analysed exons 11 and 16, which are known to cover slightly more than 70% of the whole coding region of the gene, subdivided into 4 amplicons and labelled with different fluorescent dUTPs. MD-CFLP was first utilised on a panel of 30 DNA samples in which the presence of single-base substitutions or small deletions/insertions had been previously identified by direct sequencing as gold standard, in order to define the optimal conditions in terms of PCR amplification and temperature of digestion. In a second step, we blindly analysed 21 DNA samples by MD-CFLP to verify its reliability. The sensitivity and specificity of MD-CFLP were both 100% in the first study, and 80% and 94%, respectively, in the blind sample assay. Our results demonstrate the capability of the MD-CFLP method to detect DNA sequence alterations in fragments of more than 1 kb. We conclude that CFLP is a powerful tool in mutational analysis, offering reliable results in a shorter time and at a lower cost than conventional methods, and its potential can be enhanced when internal fluorescent labelling and laser detection are used. © 2001 Cancer Research Campaign http://www.bjcancer.com

11 November 2021 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
JAJacopo Azzollini
Jacopo Azzollini
AFAndrea Ferrari
Andrea Ferrari
ASAlessandra Stracuzzi
Alessandra Stracuzzi
SCStefano Chiaravalli
Stefano Chiaravalli
MTMonica Terenziani
Monica Terenziani
SMSiranoush Manoukian
Siranoush Manoukian
DICER1 syndrome is characterized by increased susceptibility to malignancies, mostly occurring in childhood. The range of phenotypic effects of DICER1 variants is under investigation, and the syndrome’s phenotypic spectrum is steadily widening. We report on three Italian families showing heterogeneous clinical presentation and reduced penetrance in family members. Patient 1 is a 10-year-old girl with a Sertoli-Leydig cell tumor. Although family history was unremarkable, genetic testing identified a DICER1 germline variant, inherited from her healthy father. Benign thyroid nodules were subsequently diagnosed in both the proband and her father. Patient 2 is an 8-month-old boy with type 1 pleuropulmonary blastoma. His sister developed a nephroblastoma at age 2 years. A DICER1 novel variant was identified in both siblings and their healthy father. Patient 3 is a 22-year-old man who developed a spinal extramedullary intradural mass diagnosed as rhabdomyosarcoma with a peculiar tubular, gland-like component. Tumor testing revealed two pathogenic DICER1 variants, one of which was confirmed to be germline and identified in his 17-year-old healthy brother and in his father, who showed multiple thyroid nodules. Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.